drugset / Trial / NCT03039101

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101

RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Timeline

Start
2017-09-06
Primary completion
2018-07-16
Completion
2018-07-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg Oral

Indications